http://goldbamboo.com/ Fludarabine Phosphate News from GoldBamboo.com en-us © 2005, Gold Bamboo LLC, All Rights Reserved http://goldbamboo.com/news-a222160.html Today Shire plc announced the launch of FOSRENOL® (lanthanum carbonate) in the United Kingdom following the product's authorisation as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD). [click link for full article] Thu, 22 Feb 2007 06:00 EST http://goldbamboo.com/news-a219122.html UroToday.com - Allogeneic hematopoietic stem cell transplantation (BMT) for metastatic renal cell carcinoma (RCC) was first reported by Childs in 1999. In that report, patients received a conditioning regimen of fludarabine/cyclophosphamide, prior to BMT. The incidence of acute graft versus host disease (GVHD, thought to be linked to tumor response) was 53% and chronic GVHD was 21%. [click link for full article] Mon, 05 Feb 2007 04:00 EST http://goldbamboo.com/news-a217837.html JANUVIA™ (sitagliptin phosphate), Merck & Co., Inc.'s treatment for patients with type 2 diabetes, today received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) in Europe. The CHMP opinion recommends that JANUVIA be approved in the European Union for the treatment of type 2 diabetes. [click link for full article] Mon, 29 Jan 2007 08:00 EST http://goldbamboo.com/news-a213480.html A new study conducted by scientists at Children's Hospital Oakland Research Institute (CHORI) identifies a specific enzyme that can cause the death of cancer cells. Researchers studied the behavior of an enzyme called sphingosine phosphate lyase (SPL), which can regulate cell growth and death by lowering the levels of a natural, growth-promoting lipid called sphingosine-1-phosphate, or S1P. Fri, 29 Dec 2006 04:00 EST http://goldbamboo.com/news-a213649.html Biogen Idec (Nasdaq: BIIB) Biogen Idec announced data from a Phase I/II study of an investigational anti-CD23 monoclonal antibody, lumiliximab, suggesting it may be synergistic with fludarabine, cyclophosphamide and rituximab (FCR), an emerging standard of care for chronic lymphocytic leukemia (CLL) patients. [click link for full article] Tue, 02 Jan 2007 08:00 EST